The main purpose of this legislation is to ensure that lung cancer biomarker testing is covered under the Medicaid program. This is aimed at improving the precision of cancer diagnosis and treatment for individuals who rely on Medicaid for their healthcare needs. Key provisions of the legislation include the requirement for Medicaid to provide coverage for lung cancer biomarker testing. This testing helps identify specific genetic markers in lung cancer, which can guide treatment decisions and improve patient outcomes.